Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hanx Biopharmaceuticals (Wuhan) Co EBITDA Margin % Related Terms
Hanx Biopharmaceuticals (Wuhan) Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co EBITDA Margin % Chart
Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend
Dec23
Dec24
Dec25
EBITDA Margin %
0.00
0.00
0.00
Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23
Dec24
Dec25
EBITDA Margin %
0.00
0.00
0.00
HKSE:03378 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hanx Biopharmaceuticals (Wuhan) Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. According to the industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 941 companies in the Biotechnology industry.
Is Hanx Biopharmaceuticals (Wuhan) Co's EBITDA Margin % too high?
Hanx Biopharmaceuticals (Wuhan) Co's current EBITDA Margin % is 0.00%. Based on the distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 941 companies for EBITDA Margin %. This places Hanx Biopharmaceuticals (Wuhan) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. Hanx Biopharmaceuticals (Wuhan) Co's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hanx Biopharmaceuticals (Wuhan) Co Business Description
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score
Get the complete analysis for HKSE:03378
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03378 has been successfully added to your 
